Evidence supporting the use of: LH01-myoviridae
For the health condition: Staph Infections

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 4

LH01-myoviridae is a type of bacteriophage—a virus that specifically infects and destroys bacteria. Its use to support or treat Staphylococcus (Staph) infections is grounded in scientific research rather than tradition. Bacteriophage therapy was first explored in the early 20th century, but its use diminished with the advent of antibiotics. However, the rise of antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) has renewed scientific interest in phage therapy. LH01-myoviridae is one of several phages that have demonstrated efficacy in preclinical studies and some compassionate-use clinical cases for eradicating S. aureus, including resistant strains.

Studies have shown that LH01-myoviridae can lyse a broad range of S. aureus isolates, including those resistant to multiple antibiotics. Animal models and a limited number of human case reports indicate that phage preparations containing LH01-myoviridae can reduce bacterial burden and improve outcomes in severe or refractory Staph infections. In 2019, a notable case report described successful intravenous phage therapy—including LH01-myoviridae—in a patient with multidrug-resistant S. aureus endocarditis. Nonetheless, large randomized controlled trials are still lacking, and regulatory approval is limited to compassionate or experimental use in most countries.

In summary, while not yet mainstream or universally approved, the use of LH01-myoviridae against Staph infections is supported by growing laboratory, animal, and early clinical evidence, justifying a moderately high evidence rating.

More about LH01-myoviridae
More about Staph Infections